Debo Capital (australia) Pty Ltd is a limited by shares Australian proprietary company. Located at NSW 2070 since 2015-10-15 the company is, as the updated on 2021-09-09 ABN database shows, registered. Known company numbers for Debo Capital (australia) Pty Ltd are as follows: ACN - 167086571, Australian Business Number - 83167086571. Debo Capital (australia) Pty Ltd has been the company name since 2016-09-07. Their official company name changed on 2016-09-08 to Debo Capital (australia) Pty Ltd. The company had used this name up until 2021-09-09. Additionally they had used China Huayang Capital (australia) Pty Ltd from 2015-03-04 to 2016-09-08, Riveren Capital Pty Ltd from 2013-12-04 to 2015-03-04. This Australian proprietary company was previously located in VIC 3205 (from 2014-09-25 to 2015-10-15), VIC 3205 (from 2013-12-04 to 2014-09-25).
| Status | From | To |
|---|---|---|
| Active | December 4, 2013 | current |
| Name | From | To |
|---|---|---|
| Yieldstack Capital Pty Ltd | September 9, 2021 | current |
| Debo Capital (australia) Pty Ltd | September 8, 2016 | September 9, 2021 |
| China Huayang Capital (australia) Pty Ltd | March 4, 2015 | September 8, 2016 |
| Riveren Capital Pty Ltd | December 4, 2013 | March 4, 2015 |
| Location | From | To |
|---|---|---|
| NSW 2070 | October 15, 2015 | current |
| VIC 3205 | September 25, 2014 | October 15, 2015 |
| VIC 3205 | December 4, 2013 | September 25, 2014 |
Advertisements
Contains public sector information licensed under the Creative Commons Attribution 3.0 Australia licence. Material on this website was obtained from publicly-accessible databases and is attributed to ©Commonwealth of Australia 2024 (http://data.gov.au, http://acnc.gov.au/ and http://abr.business.gov.au/), ©Intellectual Property Government Open Data 2024, ©ASIC - Company Register. While we try to make the information as precise and up-to-date as possible, we are aware the datasets are not always error-free. Aubiz.net will not take responsibility for any errors in the databases. The material provided should be treated as a starting point of more in-depth research, not as fact.